NCT00077363View on ClinicalTrials.gov

Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

February 28, 2007

Conditions
Recurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

tipifarnib

Given PO

DRUG

capecitabine

Given PO

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00077363 - Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter